Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

rifosine + Bortezomib 52 1 2% 4 8% 3 6% 8 15% 12 23% With dex added* 28 0 0% 2 4% 6 12% 8 15% 11 21% Best Response N=52 1 2% 6 12% 9 17% 16 31% 23 44% (* as a subset of the evaluable population) **SD = greater than or equal to 4 cycles

Median TTP for all bortezomib-refractory patients was 6.2 months. Median TTP for responding patients has not yet been reached, currently it is 9.4 months and on-going.

Commenting on the data, Dr. Paul Richardson stated, "Perifosine appears to be particularly active with durable responses when combined with bortezomib and dexamethasone in a heavily pre-treated patient population. The encouraging response rate, impressive time to progression and manageable toxicity are especially favorable. We thus look forward to pursuing this combination in a randomized phase 3 trial."

Dr. Kenneth Anderson, Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) added, "We are excited at the results presented today as this data further confirms our early pre-clinical data demonstrating perifosine's ability to shut down bortezomib-activated AKT, which may help overcome bortezomib resistance."

Michael S. Weiss, Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We are grateful for the dedication and diligence of the team of multiple myeloma investigators, led by Dr. Paul Richardson and Dr. Kenneth Anderson, who have rapidly translated pre-clinical findings into clinical results. In this heavily pre-treated patient population, the majority of whom had failed prior bortezomib-based therapy, we believe we have demonstrated that perifosine is an active, novel agent with the potential to provide clinical benefit to patients
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Zacks.com announces the list ... Zacks Equity Research analysts discuss the latest news and events ... the blog include the Hewlett-Packard (NYSE: HPQ - Free Report ... Bulkers, Inc. (NYSE: SB - Free Report ), GlaxoSmithKline ... International N.V. (NYSE: FI - Free Report ). ...
(Date:8/21/2014)... 2014  Henry Schein, Inc. (NASDAQ: HSIC ), ... to office-based dental, animal health and medical practitioners, announced today ... September: , September 4, 2014 – Baird 2014 ... 12:50 p.m. ET , September 8, 2014 – ... York , NY at 1:25 p.m. ET ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11Henry Schein To Present At Two Investor Conferences In September 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2
... Oct. 25, 2011 Desert Radiologists has earned Breast ... and is the first facility in Las Vegas to ... The accreditation certifies that the breast MRI at Desert ... qualifications, facility equipment, quality control procedures and quality assurance ...
... 2011 Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee ... ("Epix") revealed today the contractual agreements for S1P1 lead ... 2011 in a sealed bid sale.   ... and/or developed as part of License Agreement between Amgen ...
Cached Medicine Technology:Desert Radiologists Earns ACR Breast MRI Accreditation 2Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale 2
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... teaches readers how they can use natural methods to ... years has caught the attention of Shane Michaels, prompting ... a condition that affects the skin, it can still ... from it,” reports Michaels. “The intense itching and pain ...
(Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Advancements ... for some clinical applications due to their cost-effectiveness, ... emerging innovations in ultrasound, such as the evolution ... expected to keep the market moving throughout 2014 ... mobility can enhance not only the point-of-care (POC) ...
(Date:8/22/2014)... NJ (PRWEB) August 22, 2014 ... leading specialist in Internal Medicine, Geriatrics, Hospice and ... network, CarePoint Health Medical Group. Their system welcomes ... skilled and experienced physicians comprise CarePoint Health Medical ... practices in Hudson County, representing a wide range ...
(Date:8/22/2014)... 22, 2014. A new study of self-awareness ... multiple sclerosis (MS) may be able to improve ... was epublished ahead of print on July 2 ... Hali Griswold, Nancy D. Chiaravalloti & John DeLuca: ... multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is one,s ability ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... Liquids have set out to warm up chilly Boston bus riders by heating ten bus shelters in ... the following locations: , , , 666 ... 510 Boylston Square @ Clarendon Street , ... @ Huntingdon , , , , ...
... cognition tests, study found , , MONDAY, Jan. 26 (HealthDay News) ... glucose (sugar) levels may be linked to lower brain function, ... with higher levels of hemoglobin A1C (a measure of average ... worse results while doing cognitive tasks that tested memory, speed ...
... months most susceptible, analysis finds , , MONDAY, Jan. 26 (HealthDay ... syndrome (SIDS) in the United States has declined, the rate ... a new study reports. , Such deaths have been most ... to the study, published in the February issue of ...
... ,extreme, winter sports by following these safety tipsROSEMONT, Ill., ... ("x-treme") sports can be a fun way to get ... televised events such as the X Games have led ... racing and jumping, snowboarding, snowmobiling, snow biking, and ice ...
... Brighter smiles await,children in Georgia as the Colgate-Palmolive ... Program to the Smyrna and Marietta Big,Lots stores on ... http://www.newscom.com/cgi-bin/prnh/20011026/BIGLOTSLOGO ) , ... van and its team,of dental professionals will provide free ...
... SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San ... the status of its business.Jim Hitchin, SpectraScience,s CEO, said, ... progress on all business fronts. We understand, however, that ... important to provide our shareholders with a greater level ...
Cached Medicine News:Health News:It's Cold Outside! Warm Up in Select Downtown Boston Heated Bus Shelters Courtesy of TYLENOL(r) Warming Liquids 2Health News:Higher Blood Sugar Could Impair Thinking 2Health News:More Accidental Infant Deaths Blamed on Suffocation in Bed 2Health News:More Accidental Infant Deaths Blamed on Suffocation in Bed 3Health News:More Accidental Infant Deaths Blamed on Suffocation in Bed 4Health News:'X-Tremely' Dangerous Sports 2Health News:'X-Tremely' Dangerous Sports 3Health News:Colgate's Bright Smiles, Bright Futures Program Brings Free Children's Dental Screenings to Atlanta Area Big Lots Stores 2Health News:SpectraScience Announces Business Update 2Health News:SpectraScience Announces Business Update 3
... is the most common cause ... 5% of pediatric visits and ... under 5 years. ImmunoSTAT! Rotatvirus ... rule in or rule out ...
... delivers 100% specificity and 100% PPV ... With as many as one-fourth ... this assay provides a test & ... detection and treatment while reducing overall ...
Shielding's Wrap-Around Apron is designed for front and back protection. This apron features extra wide shoulders distributing weight over a greater area to reduce fatigue....
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps....
Medicine Products: